Teva Pharma Industries Ltd ADR

Teva Pharma Industries Ltd ADR

Yahoo Finance • 13 hours ago

BioXcel files for Chapter 11, will sell assets to Teva

[Businessman reads Bankruptcy Chapter 11 book.] designer491 * BioXcel Therapeutics (BTAI [https://seekingalpha.com/symbol/BTAI]) filed for Chapter 11 [https://seekingalpha.com/pr/20633273-bioxcel-therapeutics-enters-into-asset-sale-agre... Full story

Yahoo Finance • 3 days ago

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Both Neurocrine Biosciences NBIX and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions. NBIX focuses on neuroscience, with growth primarily led by... Full story

Yahoo Finance • 3 days ago

Teva business practices under scrutiny in Turkish antitrust probe

[Building of Teva Canada Markham manufacturing facility.] JHVEPhoto/iStock Editorial via Getty Images Turkish regulators have launched an investigation into whether Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) violate... Full story

Yahoo Finance • 8 days ago

Alvotech Q2 Earnings Call Highlights

Key Points Interested in Alvotech? Here are five stocks we like better. First-half results declined as manufacturing slowed during facility and quality-system improvements, with revenue falling to $212 million and adjusted EBITDA to $47 m... Full story

Yahoo Finance • 9 days ago

Aurinia settles Lupkynis patent litigation with Teva

[Intellectual Property] stocknshares * Teva Pharmaceutical Industries (TEVA [https://seekingalpha.com/symbol/TEVA]) will not be able to launch a generic version of Aurinia Pharmaceuticals' (AUPH [https://seekingalpha.com/symbol/AUPH]) L... Full story

Yahoo Finance • 16 days ago

ADAMA Appoints Orly Pascal as Chief Human Resources Officer

BEIJING and TEL AVIV, Israel, Aug. 13, 2026 /PRNewswire/ -- ADAMA Ltd. (SZSE: 000553), a leading global crop protection company, today announced the appointment of Orly Pascal as Chief Human Resources Officer (CHRO), and her joining ADAMA'... Full story

Yahoo Finance • 26 days ago

Why Teva Pharmaceutical Stock Surged This Week

Teva Pharmaceutical (NYSE: TEVA) stock closed out the last week of trading with significant gains, rising roughly 12.3% across the stretch. The S&P 500 gained 0.2% over the same period, and the Nasdaq Composite was up approximately 0.5%.... Full story

Yahoo Finance • 29 days ago

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging th... Full story

Yahoo Finance • 29 days ago

Teva Pharmaceutical Industries Q2 Earnings Call Highlights

MarketBeat Week in Review – 02/03 - 02/07 Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid wer... Full story

Yahoo Finance • 30 days ago

Teva outlines higher 2026 revenue midpoint by $75M while targeting AUSTEDO $2.45B-$2.6B and AJOVY $850M-$870M

Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 MANAGEMENT VIEW * "On delivery on our growth engines, AUSTEDO, AJOVY, and UZEDY all delivered strong Q2 performance, and we are raising our full-year revenue... Full story

Yahoo Finance • 30 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...

This article first appeared on GuruFocus. Revenue: Approximately $4.1 billion, down 1% in U.S. Dollars or 3% in local currency compared to Q2 2025. Net Loss: $576 million. Non-GAAP Gross Margin: 55.4%, an increase of 80 basis points year-... Full story

Yahoo Finance • 30 days ago

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acqu... Full story

Yahoo Finance • last month

Teva Stock Is Rebounding. Its Drug Pipeline Holds the Key to Growth.

Teva can look beyond President Donald Trump’s threat of a tariff on generic drugs. Teva has a pipeline of branded drugs that has caught Wall Street’s attention. Continue Reading... Full story

Yahoo Finance • last month

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.

Year to date, Teva Pharmaceutical Industries (NYSE: TEVA) shares have continued to recover. Thanks to the company's shifting focus from generic to branded drugs, this pharmaceutical stock has surged by around 85% over the past 12 months.... Full story

Yahoo Finance • last month

Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat

President Donald Trump’s threat of 100% tariffs on generic drugs would seem to be a problem for Teva Pharmaceutical. It might not be. Continue Reading... Full story

Yahoo Finance • last month

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

Determining where to allocate capital in the healthcare sector often involves choosing between established stability and aggressive growth. Both Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Co (NYSE:LLY) offer unique paths for investors.... Full story

Yahoo Finance • 2 months ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Choosing between Novartis AG (NYSE:NVS) and Teva Pharmaceutical Industries (NYSE:TEVA) requires weighing the stability of an established innovator against the potential of a generic specialist undergoing a significant turnaround. Novartis... Full story

Yahoo Finance • 2 months ago

Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar

(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA) and Polpharma Biologics International AG announced Thursday a global licensing agreement granting Teva exclusive rights to comme... Full story

Yahoo Finance • 2 months ago

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Key Points Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and expands its biosimilar port... Full story

Yahoo Finance • 2 months ago

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Key Points Arcutis Biotherapeutics is rapidly scaling its Zoryve dermatology line with revenue doubling in its most recent fiscal year. Vertex Pharmaceuticals maintains a dominant position in cystic fibrosis while successfully expanding i... Full story